Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
53.4M
-
Shares change
-
+3.22M
-
Total reported value, excl. options
-
$348M
-
Value change
-
+$19.4M
-
Put/Call ratio
-
0.48
-
Number of buys
-
58
-
Number of sells
-
-27
-
Price
-
$6.51
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2023
104 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2023.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.4M shares
of 98.6M outstanding shares and own 54.18% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (11.1M shares), ORBIMED ADVISORS LLC (8.74M shares), FMR LLC (5.09M shares), SR ONE CAPITAL MANAGEMENT, LP (4.01M shares), Rubric Capital Management LP (3.48M shares), RA CAPITAL MANAGEMENT, L.P. (3.01M shares), K2 PRINCIPAL FUND, L.P. (2.69M shares), BAKER BROS. ADVISORS LP (2.01M shares), Nextech Invest Ltd. (1.91M shares), and VANGUARD GROUP INC (1.7M shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.